Canaccord Genuity Starts Chembio Diagnostics (CEMI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Strong earthquake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Chembio Diagnostics (CEMI) Secures CE Mark for Point-of-Care Diagnostic Test Developed in Collaboration with AstraZeneca (AZN)
January 7, 2019 7:22 AM ESTChembio Diagnostics, Inc. (NASDAQ: CEMI) today announced that it has received a CE mark for its diagnostic test developed in collaboration with AstraZeneca, a global biopharmaceutical company.
Chembio and AstraZeneca have collaborated to develop a quantitative diagnostic test to detect an... More
